Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies

Gabriel Levy, Nicolas Papadopoulos, Christian Pecquet, Jean-Philippe Defour, Emilie Leroy, Nabih Maslah, Bruno Cassinat, Steven Smith, Stefan N Constantinescu

Blood (2022) 140 (Supplement 1): 8736–8737.

https://doi.org/10.1182/blood-2022-168663

Published: 2022

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Blood (2019) 133 (25): 2669–2681.

https://doi.org/10.1182/blood-2018-09-874578

Published: 2019

Includes: Supplemental data

Journal Articles

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

Cristina Mambet, Olga Babosova, Jean-Philippe Defour, Emilie Leroy, Laura Necula, Oana Stanca, Aurelia Tatic, Nicoleta Berbec, Daniel Coriu, Monika Belickova, Barbora Kralova, Lucie Lanikova, Jitka Vesela, Christian Pecquet, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, Vladimir Divoky, Stefan N. Constantinescu

Blood (2018) 132 (25): 2695–2699.

https://doi.org/10.1182/blood-2018-04-843060

Published: 2018

Includes: Supplemental data

Journal Articles

JAK2 V617F Dimerizes Homodimeric Cytokine Receptors Cytosolic Domains By Requiring Pseudokinase Domain Residues That Promote JAK2 Dimerization and Oncogenic Activity

Emilie Leroy, Thomas Balligand, MD, Stefan N Constantinescu, MD

Blood (2018) 132 (Supplement 1): 50.

https://doi.org/10.1182/blood-2018-99-111336

Published: 2018

Journal Articles

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Cristina Mambet, MD, Jean-Philippe Defour, BPharm, PhD, Olga Babosova, M.Sc., Emilie Leroy, Laura Necula, PhD, Oana Stanca, MD, Aurelia Tatic, MD, Daniel Coriu, MD, Monika Belickova, PhD, Barbora Kralova, MSc, Lucie Lanikova, PhD, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, PhD, Vladimir Divoky, PhD, Stefan N Constantinescu, MD

Blood (2018) 132 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2018-99-117019

Published: 2018

Journal Articles

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL

Sandrine Degryse, Simon Bornschein, Charles E. de Bock, Emilie Leroy, Marlies Vanden Bempt, Sofie Demeyer, Kris Jacobs, Ellen Geerdens, Olga Gielen, Jean Soulier, Christine J. Harrison, Stefan N. Constantinescu, Jan Cools

Blood (2018) 131 (4): 421–425.

https://doi.org/10.1182/blood-2017-07-797597

Published: 2018

Includes: Supplemental data

Journal Articles

A Novel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor

Ami B. Patel, MD, Anca Franzini, PhD, Emilie Leroy, PhD, Dongqing Yan, Anna M. Eiring, PhD, Stefan N. Constantinescu, MD PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 4212.

https://doi.org/10.1182/blood.V130.Suppl_1.4212.4212

Published: 2017

Journal Articles

Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia

Katarina Kapralova, Monika Horvathova, Christian Pecquet, Jana Fialova Kucerova, Dagmar Pospisilova, Emilie Leroy, Barbora Kralova, Jelena D. Milosevic Feenstra, Fiorella Schischlik, Robert Kralovics, Stefan N. Constantinescu, Vladimir Divoky

Blood (2016) 128 (10): 1418–1423.

https://doi.org/10.1182/blood-2016-02-698951

Published: 2016

Includes: Supplemental data

Journal Articles

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Blood (2016) 127 (3): 325–332.

https://doi.org/10.1182/blood-2015-07-661835

Published: 2016

Includes: Supplemental data

Journal Articles

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Jelena D Milosevic Feenstra, PhD, Harini Nivarthi, PhD, Heinz Gisslinger, MD, Emilie Leroy, Elisa Rumi, MD, Ilyas Chachoua, Klaudia Bagienski, Blanka Kubesova, MSc, Daniela Pietra, PhD, Bettina Gisslinger, Roland Jäger, PhD, Doris Chen, PhD, Tiina Berg, B.Sc., Martin Schalling, MSc, Michael Schuster, PhD, Christoph Bock, PhD, Stefan N. Constantinescu, MD PhD, Mario Cazzola, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 606.

https://doi.org/10.1182/blood.V126.23.606.606

Published: 2015

Journal Articles

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Lorraine Springuel, Tekla Hornakova, Elisabeth Losdyck, Fanny Lambert, Emilie Leroy, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Laurent Knoops, Jean-Christophe Renauld

Blood (2014) 124 (26): 3924–3931.

https://doi.org/10.1182/blood-2014-05-576652

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5

Katarina Kapralova, MSc, Monika Horvathova, PhD, Jana Kucerova, PhD, Dagmar Pospisilova, MD PhD, Emilie Leroy, Stefan N. Constantinescu, MD PhD, Vladimir Divoky, PhD

Blood (2014) 124 (21): 4008.

https://doi.org/10.1182/blood.V124.21.4008.4008

Published: 2014

Journal Articles

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Caroline Marty, Cécile Saint-Martin, Christian Pecquet, Sarah Grosjean, Joseph Saliba, Céline Mouton, Emilie Leroy, Ashot S. Harutyunyan, Jean-François Abgrall, Rémi Favier, Aurélie Toussaint, Eric Solary, Robert Kralovics, Stefan N. Constantinescu, Albert Najman, William Vainchenker, Isabelle Plo, Christine Bellanné-Chantelot

Blood (2014) 123 (9): 1372–1383.

https://doi.org/10.1182/blood-2013-05-504555

Published: 2014

Includes: Supplemental data

NARROW

Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

JAK2 V617F Dimerizes Homodimeric Cytokine Receptors Cytosolic Domains By Requiring Pseudokinase Domain Residues That Promote JAK2 Dimerization and Oncogenic Activity

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL

A Novel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor

Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only